ABSTRACT: Background: Several commercial and academic autologous chimeric antigen receptor T-cell products targeting CD19 have bee n approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma, and mantl ...